US private equity firm Warburg Pincus has successfully completed the acquisition of Mumbai-based formulations company Integrace Health in a deal valued at approximately ₹1,200 crore, according to reports from people familiar with the matter. The transaction represents a significant milestone in the Indian pharmaceutical sector, marking Warburg Pincus's expansion of its healthcare investments in India. In this landmark transaction, Warburg Pincus has demonstrated its commitment to building scaled, market-leading pharmaceuticals businesses in India through strategic acquisitions.
The acquisition marks the full exit of existing shareholders True North and Singapore state investor Temasek, transferring ownership of the specialty pharmaceuticals company to Warburg Pincus. As per The Economic Times, True North Fund VI LLP holds a 55.83% stake in Integrace, while Temasek arm V-Science Investments Pte owns 43.91%. This strategic divestment allows both investors to realize returns on their investment in the Mumbai-based healthcare company, reflecting the selective approach to market participation that industry experts recommend during current market conditions.
Industry veteran Rehan Khan, former Managing Director at MSD and Abbott India Limited, will join Integrace as Chief Executive Officer to lead the company's next phase of growth in partnership with Warburg Pincus. Khan's extensive experience in the pharmaceutical sector is expected to drive the company's expansion strategy under the new ownership structure, with his focus on the celebrated orthopedic and gynecological brands that have built Integrace's strong market position. As reported by The Economic Times, Khan stated that "India's pharmaceutical market is large and attractive, with predictable long-term growth, particularly in women's health and orthopedic therapies."
According to Warburg Pincus Managing Director Himanshu Nema, the acquisition reflects the firm's conviction in therapy-focused, brand-led platforms and ambition to build a scaled, market-leading pharmaceuticals business in India. As reported by The Economic Times, Nema emphasized that "This acquisition reflects our conviction in therapy-focused, brand-led platforms and our ambition to build a scaled, market-leading pharmaceuticals business in India." Integrace has built an exceptional foundation with a differentiated portfolio in orthopedics and gynecology, a strong position in the high-growth therapeutics segments and trusted relationships with specialists. The company's focus on these specialized therapeutic areas positions it well in the current market environment where experts recommend selective investment approaches.
Incorporated in August 2018, Integrace commenced operations by acquiring a portfolio of branded generic businesses from Glenmark Pharmaceuticals later that year. According to The Economic Times, in October 2018, it bought Glenmark's gynaecology business for ₹115 crore in cash, followed by the acquisition of the company's orthopaedic and pain management (OPM) business in India and Nepal in a transaction valued at ₹635 crore. Integrace expanded its gynaecology franchise in 2021 through the acquisition of the Mifegest and Cytolog brands from Zydus Healthcare. The company's brands in the OPM segment, including Lizolid and Stiloz, are the largest contributors to revenue, followed by Esoz. In the gynaecology segment, Mifegest is the largest contributor, followed by Cytolog, Fenza and Mumfer. Satish Chander, Partner at True North, expressed pride in partnering with the Integrace team, stating that they built it into a strong, quality healthcare company that established a deep and respectable position among specialists through its science-based marketing practices.
